Weight Watchers has outlasted diet fads, rebrands and even logic. But this time, it’s not carbs or keto that brought it down ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

Pfizer has ended development of danuglipron, an oral GLP-1 drug for weight management, citing clinical data and regulatory input.

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Consumers may cycle on and off GLP-1 medications because of financial constraints. These consumers present opportunities for ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

A statistically significantly lower risk of dementia or cognitive impairment was observed with GLP-1RAs, though not with SGLT2is or pioglitazone.

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...